agilon health(US:AGL) Businesswire·2026-01-12 23:00Core Viewpoint - A class action lawsuit has been filed against agilon health, inc. for allegedly making false statements and failing to disclose critical information regarding its financial guidance and strategic actions during the class period from February 26, 2025, to August 2, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that agilon issued guidance for 2025 that it knew or should have known was unattainable due to significant industry challenges [1] - It is alleged that agilon materially overstated the immediate positive financial impact from its strategic actions aimed at reducing risk [1] - Investors who suffered losses on their agilon investments have until March 2, 2026, to request lead plaintiff appointment [1] Group 2: Leadership Transition and Financial Results - On August 4, 2025, agilon announced the resignation of Steven Sell as President, CEO, and Director, which was classified as a termination without cause [2] - The company suspended its previously issued full-year 2025 financial guidance, acknowledging that industry headwinds were more severe than anticipated [2] - Following this announcement, agilon's share price fell by $0.94, approximately 51.6%, from $1.82 to $0.88 [2] Group 3: Lead Plaintiff Appointment Process - The federal securities laws allow any investor who acquired eligible securities during the class period to seek appointment as lead plaintiff in the class action lawsuit [3] - Courts typically appoint investors with the largest financial loss rather than those with the largest investment portfolio [3] - Lead plaintiffs have significant influence over case strategy, settlement decisions, and allocation of settlement funds among class members [3]